Cognitive O
control O
network O
dysconnectivity O
and O
response O
to O
antipsychotic O
treatment O
in O
schizophrenia O
To O
better O
understand O
cognitive O
control O
impairment O
in O
schizophrenia O
, O
it O
is O
vital O
to O
determine O
the O
extent O
of O
dysfunctional O
connectivity O
in O
the O
associated O
fronto-striatal O
brain O
network O
, O
with O
a O
focus O
on O
the O
connections O
with O
the O
anterior O
cingulate O
cortex O
( O
ACC O
) O
, O
prior O
to O
the O
potential O
confounding O
effect O
of O
medication O
. O

It O
is O
also O
essential O
to O
determine O
the O
effects O
following O
antipsychotic O
medication O
and O
the O
relationship O
of O
those O
effects O
on O
psychosis O
improvement O
. O

Twenty-two O
patients O
with O
schizophrenia O
, O
initially O
unmedicated O
and O
after O
a O
6-week O
course O
of O
risperidone O
, O
and O
20 O
matched O
healthy O
controls O
( O
HC O
) O
performed O
a O
fMRI O
task O
twice O
, O
six O
weeks O
apart O
. O

We O
investigated O
group O
and O
longitudinal O
differences O
in O
ACC-related O
functional O
connectivity O
during O
performance O
of O
a O
Stroop O
color O
task O
as O
well O
as O
connectivity O
patterns O
associated O
with O
improvement O
in O
psychosis O
symptoms O
. O

Unmedicated O
patients O
with O
schizophrenia O
showed O
greater O
functional O
connectivity O
between O
ACC O
and O
bilateral O
caudate O
and O
midbrain O
and O
lower O
connectivity O
with O
left O
putamen O
compared O
to O
healthy O
controls O
. O

At O
baseline O
, O
greater O
functional O
connectivity O
between O
ACC O
and O
bilateral O
putamen O
predicted O
subsequent O
better O
treatment O
response O
. O

Change O
in O
functional O
connectivity O
between O
ACC O
and O
left O
putamen O
positively O
correlated O
with O
better O
treatment O
response O
. O

These O
results O
suggest O
that O
patterns O
of O
functional O
connectivity O
in O
fronto-striatal O
networks O
can O
be O
utilized O
to O
predict O
potential O
response O
to O
antipsychotic O
medication O
. O

Prior O
to O
treatment O
, O
brain O
function O
may O
be O
structured O
with O
a O
predisposition O
that O
favors O
or O
not O
treatment O
response O
. O

Methods O
Twenty-eight O
subjects O
with O
schizophrenia O
or O
schizoaffective O
disorder O
( O
SZ O
) O
were O
recruited O
for O
this O
study O
from O
the O
psychiatry O
clinics O
and O
emergency O
room O
at O
the O
University O
of O
Alabama O
at O
Birmingham O
( O
UAB O
) O
based O
on O
being O
off O
antipsychotic O
medication O
for O
at O
least O
10 O
days O
. O

Twenty-five O
healthy O
controls O
( O
HC O
) O
, O
matched O
on O
age O
, O
sex O
, O
smoking O
, O
and O
parental O
occupation O
, O
without O
personal O
or O
family O
history O
in O
a O
first-degree O
relative O
of O
psychiatric O
disorders O
were O
recruited O
using O
advertisements O
. O

Exclusion O
criteria O
were O
major O
medical O
or O
neurological O
conditions O
, O
substance O
use O
disorders O
( O
except O
for O
nicotine O
) O
within O
six O
months O
of O
imaging O
( O
drug O
screen O
was O
done O
prior O
to O
scanning O
) O
, O
head O
injury O
with O
loss O
of O
consciousness O
> O
2 O
minutes O
, O
and O
pregnancy O
. O

Subjects O
gave O
written O
informed O
consent O
prior O
to O
participating O
in O
this O
UAB O
Institutional O
Review O
Board O
approved O
study O
. O

Diagnoses O
were O
established O
using O
subjects O
’ O
medical O
records O
and O
the O
Diagnostic O
Interview O
for O
Genetic O
Studies O
( O
DIGS O
) O
. O

The O
Repeatable O
Battery O
for O
the O
Assessment O
of O
Neuropsychological O
Status O
( O
RBANS O
) O
characterized O
general O
cognitive O
function O
. O

SZ O
were O
scanned O
while O
unmedicated O
and O
after O
a O
six-week O
trial O
with O
risperidone O
. O

Medication O
was O
managed O
by O
two O
psychiatrists O
( O
ACL O
and O
NVK O
) O
, O
and O
dose O
determinations O
were O
based O
on O
therapeutic O
and O
side O
effects O
. O

Starting O
doses O
were O
1–3mg O
; O
titration O
was O
done O
in O
1–2mg O
increments O
. O

Use O
of O
concomitant O
medications O
was O
permitted O
as O
clinically O
indicated O
. O

Symptom O
severity O
was O
assessed O
weekly O
using O
the O
Brief O
Psychiatric O
Rating O
Scale O
( O
BPRS O
) O
. O

Medication O
compliance O
was O
monitored O
by O
weekly O
pill O
count O
. O

HC O
were O
scanned O
twice O
six O
weeks O
apart O
. O

Subjects O
were O
excluded O
due O
to O
excess O
movement O
( O
> O
2mm O
translation O
; O
2° O
rotation O
within O
a O
run O
; O
4 O
SZ O
, O
2 O
HC O
) O
or O
lack O
of O
complete O
task O
performance O
, O
defined O
as O
no O
responses O
to O
more O
than O
¼ O
of O
the O
total O
number O
of O
trials O
, O
( O
2 O
SZ O
baseline O
, O
2 O
SZ O
week O
six O
, O
3 O
HC O
) O
, O
leaving O
22 O
SZ O
and O
20 O
HC O
at O
baseline O
and O
20 O
SZ O
and O
20 O
HC O
at O
week O
six O
. O

Task O
Subjects O
performed O
a O
computerized O
version O
of O
the O
Stroop O
color-naming O
task O
. O

Stimuli O
consisted O
of O
three O
words O
: O
“ O
RED O
” O
, O
“ O
GREEN O
” O
, O
or O
“ O
BLUE O
, O
” O
displayed O
in O
one O
of O
the O
corresponding O
colors O
. O

Trials O
were O
either O
“ O
congruent O
” O
or O
“ O
incongruent O
, O
” O
where O
the O
word O
and O
the O
color O
of O
the O
word O
differed O
in O
incongruent O
trials O
. O

Subjects O
were O
instructed O
to O
indicate O
the O
color O
but O
ignore O
the O
word O
and O
to O
respond O
as O
quickly O
and O
as O
accurately O
as O
possible O
. O

Responses O
were O
recorded O
by O
button O
press O
using O
an O
IFIS-SA O
system O
( O
In O
Vivo O
, O
Orlando O
, O
Florida O
) O
running O
E-Prime O
( O
version O
1.2 O
; O
Psychology O
Software O
Tools O
, O
Pittsburgh O
, O
Pennsylvania O
) O
. O

The O
event-related O
design O
consisted O
of O
three O
runs O
of O
88 O
trials O
per O
run O
( O
~30 O
% O
incongruent O
, O
70 O
% O
congruent O
) O
. O

The O
3 O
seconds O
trials O
were O
comprised O
of O
a O
word O
stimulus O
for O
1.5 O
seconds O
and O
a O
fixation O
cross O
for O
1.5 O
seconds O
. O

Subjects O
completed O
a O
practice O
run O
before O
each O
scanning O
session O
. O

Image O
Acquisition O
Imaging O
was O
performed O
on O
a O
3T O
head-only O
MRI O
scanner O
( O
Magnetom O
Allegra O
, O
Siemens O
Medical O
Solutions O
, O
Erlangen O
, O
Germany O
) O
, O
with O
a O
circularly O
polarized O
transmit/receive O
head O
coil O
. O

fMRI O
data O
were O
acquired O
using O
the O
gradient O
recalled O
echo-planar O
imaging O
sequence O
( O
repetition O
time/echo O
time O
[ O
TR/TE O
] O
= O
2100/30 O
milliseconds O
, O
flip O
angle= O
70° O
, O
field O
of O
view= O
24× O
24cm2 O
, O
64 O
× O
64 O
matrix O
, O
4mm O
slice O
thickness O
, O
1mm O
gap O
, O
26 O
axial O
slices O
) O
. O

A O
high-resolution O
structural O
scan O
was O
acquired O
for O
anatomical O
reference O
( O
MPRAGE O
; O
TR/TE/inversion O
time O
[ O
TI O
] O
= O
2300/3.93/1100 O
milliseconds O
, O
flip O
angle= O
12° O
, O
256 O
× O
256 O
matrix O
, O
1mm3 O
voxel O
size O
) O
. O

Analyses O
between O
groups O
and O
across O
time O
found O
no O
significant O
differences O
in O
mean O
scan-to-scan O
head O
movement O
for O
the O
six O
movement O
parameters O
. O

Statistical O
Analysis O
Analyses O
were O
conducted O
in O
SPSS O
20 O
( O
IBM O
SPSS O
Inc. O
, O
Chicago O
, O
IL O
) O
. O

Group O
comparisons O
were O
performed O
using O
chi-square O
or O
analysis O
of O
variance O
, O
as O
appropriate O
. O

Analyzes O
of O
reaction O
time O
( O
RT O
) O
for O
correct O
trials O
[ O
congruent O
, O
incongruent O
, O
and O
Stroop O
( O
incongruent O
- O
congruent O
) O
] O
and O
errors O
( O
congruent O
, O
incongruent O
) O
were O
analyzed O
using O
linear O
mixed O
models O
comparing O
fixed O
effects O
of O
group O
( O
HC O
vs O
SZ O
) O
, O
time O
( O
unmedicated O
vs O
week O
six O
) O
, O
condition O
( O
congruent O
vs O
incongruent O
) O
, O
and O
interactions O
. O

Post O
hoc O
analyses O
were O
performed O
where O
appropriate O
with O
Bonferroni O
corrections O
. O

Image O
analyses O
Data O
analyses O
were O
implemented O
in O
SPM8 O
( O
Wellcome O
Trust O
Centre O
for O
Neuroimaging O
) O
. O

Preprocessing O
included O
slice-timing O
correction O
, O
realignment O
, O
reslicing O
at O
1.5mm O
isotropic O
voxels O
, O
motion/artifact O
correction O
using O
ArtRepair O
, O
DARTEL O
normalization O
, O
and O
smoothing O
( O
4mm O
full O
width O
at O
half O
maximum O
Gaussian O
kernel O
) O
. O

Analysis O
for O
the O
Stroop O
task O
consisted O
of O
a O
single-subject O
voxel-by-voxel O
general O
linear O
model O
. O

Five O
conditions O
were O
included O
: O
incongruent O
, O
congruent O
, O
stimulus O
repetitions O
( O
exact O
repetition O
of O
a O
previous O
trial O
) O
, O
error O
, O
and O
no O
response O
trials O
. O

The O
conditions O
were O
convolved O
with O
the O
canonical O
hemodynamic O
response O
function O
with O
temporal O
derivatives O
. O

The O
contrast O
of O
interest O
was O
correct O
incongruent O
trials O
minus O
correct O
congruent O
trials O
, O
subsequently O
referred O
to O
as O
the O
Stroop O
effect O
. O

A O
contrast O
z-map O
of O
the O
BOLD O
signal O
during O
the O
Stroop O
effect O
was O
generated O
for O
each O
subject O
at O
each O
time O
point O
. O

Generalized O
psycho-physiological O
interaction O
( O
gPPI O
) O
is O
an O
analysis O
method O
that O
investigates O
functional O
connectivity O
between O
a O
selected O
brain O
region O
and O
the O
rest O
of O
the O
brain O
during O
the O
presence O
of O
task O
conditions O
. O

gPPI O
analysis O
is O
an O
interaction O
analysis O
that O
allows O
one O
to O
analyze O
changes O
in O
connectivity O
across O
conditions O
, O
in O
this O
case O
between O
the O
incongruent O
and O
congruent O
conditions O
, O
and O
allows O
more O
flexibility O
in O
analyses O
compared O
to O
standard O
PPI O
. O

Stroop O
effect-dependent O
connectivity O
with O
the O
ACC O
( O
defined O
using O
the O
IBASPM O
116 O
WFU O
pickatlas O
with O
subsequent O
restriction O
of O
being O
one O
slice O
forward O
from O
the O
disappearance O
of O
the O
juncture O
of O
the O
anterior O
corpus O
callosum O
from O
both O
hemispheres O
and O
the O
posterior O
end O
as O
the O
first O
vertical O
slice O
posterior O
to O
the O
anterior O
commissure O
) O
was O
assessed O
using O
the O
gPPI O
toolbox O
. O

On O
first-level O
, O
the O
gPPI O
analysis O
included O
the O
following O
regressors O
: O
the O
psychological O
component O
of O
the O
task O
condition O
( O
congruent O
, O
incongruent O
) O
, O
the O
physiological O
component O
( O
time O
course O
of O
activation O
in O
the O
ACC O
region O
) O
and O
the O
psychophysiological O
interaction O
of O
these O
two O
components O
throughout O
the O
whole O
brain O
. O

The O
Stroop O
effect O
contrast O
condition O
was O
created O
by O
subtracting O
the O
gPPI O
interaction O
regressor O
of O
the O
congruent O
condition O
from O
the O
interaction O
regressor O
of O
the O
incongruent O
condition O
. O

A O
contrast O
map O
of O
the O
interaction O
of O
interest O
, O
Stroop O
effect O
× O
ACC O
activation O
interaction O
, O
was O
generated O
for O
each O
subject O
at O
each O
time O
point O
. O

On O
second-level O
, O
between- O
group O
differences O
for O
baseline O
ACC-Stroop O
effect O
functional O
connectivity O
were O
characterized O
via O
a O
two-sample O
t-test O
within O
SPM O
. O

Exploratory O
analyses O
: O
in O
regions O
where O
baseline O
functional O
connectivity O
was O
significantly O
different O
between O
groups O
, O
the O
first O
eigenvariate O
of O
functional O
connectivity O
was O
extracted O
for O
each O
individual O
via O
REX O
( O
CIBSR O
Stanford O
University O
, O
CA O
) O
using O
a O
6mm O
sphere O
centered O
on O
the O
maximum O
intensity O
projections O
; O
these O
values O
were O
plotted O
against O
average O
errors O
and O
Stroop O
RT O
and O
R2 O
values O
( O
converted O
to O
z O
) O
compared O
between O
groups O
. O

Outlier O
values O
beyond O
two O
standard O
deviations O
were O
removed O
from O
the O
descriptive O
plots O
and O
correlation O
analysis O
between O
connectivity O
values O
and O
Stroop O
performance O
( O
RT O
and O
errors O
) O
values O
. O

To O
examine O
APD O
effects O
on O
functional O
connectivity O
, O
we O
employed O
a O
full O
factorial O
analysis O
. O

Independent O
variables O
were O
included O
for O
group O
( O
HC O
vs O
SZ O
) O
, O
time O
( O
unmedicated/baseline O
vs O
week O
six O
) O
and O
the O
interaction O
of O
group O
and O
time O
( O
group O
× O
time O
) O
. O

Contrast O
images O
were O
generated O
for O
the O
group O
× O
time O
interaction O
. O

To O
correctly O
partition O
the O
variance O
for O
valid O
interpretation O
of O
the O
main O
effects O
of O
group O
and O
time O
independent O
sample O
t-tests O
and O
paired-sample O
t-tests O
were O
run O
. O

In O
the O
presence O
of O
a O
significant O
group O
× O
time O
interaction O
, O
functional O
connectivity O
values O
were O
extracted O
at O
the O
individual O
level O
using O
REX O
. O

For O
each O
group O
, O
we O
correlated O
the O
change O
in O
functional O
connectivity O
between O
regions O
identified O
in O
the O
group O
× O
time O
interaction O
and O
compared O
R2 O
values O
between O
groups O
. O

Linear O
regression O
was O
used O
to O
determine O
whether O
functional O
connectivity O
at O
baseline O
in O
unmedicated O
SZ O
was O
related O
to O
subsequent O
treatment O
response O
and O
to O
determine O
whether O
changes O
in O
functional O
connectivity O
over O
the O
course O
of O
6 O
weeks O
were O
related O
to O
treatment O
response O
. O

For O
the O
latter O
, O
contrast O
images O
were O
created O
using O
IMCalc O
( O
Stroop O
week O
6 O
– O
Stroop O
baseline O
) O
and O
then O
entered O
into O
the O
regression O
. O

To O
visualize O
the O
distribution O
of O
variance O
associated O
with O
these O
analyses O
, O
we O
extracted O
the O
first O
eigenvariate O
of O
the O
effect O
of O
interest O
in O
regions O
where O
treatment O
response O
was O
correlated O
with O
treatment O
response O
and O
plotted O
the O
extracted O
values O
( O
z-scores O
) O
against O
treatment O
response O
. O

Treatment O
response O
was O
defined O
as O
the O
percent O
change O
on O
the O
BPRS O
psychosis O
subscale O
from O
baseline O
( O
A O
) O
to O
six O
weeks O
of O
risperidone O
( O
B O
) O
: O
Analyses O
were O
corrected O
for O
multiple O
comparisons O
using O
small-volume-correction O
( O
SVC O
) O
in O
accordance O
with O
Gaussian O
random O
field O
theory O
( O
p O
< O
0.05 O
) O
. O

In O
order O
to O
observe O
functional O
connectivity O
in O
the O
network O
of O
interest O
, O
results O
were O
restricted O
with O
a O
mask O
containing O
regions O
of O
the O
fronto-striatal O
network O
. O

The O
fronto-striatal O
network O
mask O
was O
composed O
of O
the O
putamen O
and O
caudate O
from O
IBASPM O
116 O
and O
midbrain O
from O
TD O
lobes O
as O
part O
of O
the O
WFU O
pickatlas O
. O

An O
image O
of O
the O
composed O
mask O
is O
provided O
in O
Supplement O
Fig O
. O

1 O
. O

